SCHEMBL23723002

SCHEMBL23723002

O=C(O)c1cccc(-n2[nH]c3c(c2=O)CCCC3)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.71
MEN1 O00255 8/20 0.71
ALDH1A1 P00352 6/20 0.71
L3MBTL1 Q9Y468 5/20 0.71
POLB P06746 3/20 0.71
TDP1 Q9NUW8 2/20 0.71
HPGD P15428 2/20 0.50
CYP1A2 P05177 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
KDM4E B2RXH2 3/20 0.48
GAA P10253 3/20 0.48
HSD17B10 Q99714 2/20 0.48
NPC1 O15118 1/20 0.46
MITF O75030 1/20 0.46
RAB9A P51151 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31747051 1.00 KMT2A (0.71) KMT2AMEN1ALDH1A1L3MBTL1POLB
SCHEMBL3532027 0.81 MEN1 (1.00) KMT2AMEN1ALDH1A1L3MBTL1POLB
SCHEMBL3535509 0.80 MEN1 (0.97) KMT2AMEN1ALDH1A1L3MBTL1POLB
SCHEMBL11269804 0.78 MEN1 (0.93) KMT2AMEN1ALDH1A1L3MBTL1POLB
SCHEMBL692284 0.70 KDM2B (0.56) KMT2AMEN1ALDH1A1L3MBTL1POLB
SCHEMBL9871954 0.69 TYMS (0.58) KMT2AMEN1ALDH1A1L3MBTL1POLB
SCHEMBL11595466 0.69 MEN1 (0.69) KMT2AMEN1ALDH1A1L3MBTL1POLB
SCHEMBL7894742 0.68 ALDH1A1 (0.70) KMT2AMEN1ALDH1A1L3MBTL1POLB
SCHEMBL15789002 0.68 ALDH1A1 (0.94) KMT2AMEN1ALDH1A1L3MBTL1POLB
SCHEMBL20053775 0.67 ALDH1A1 (0.66) KMT2AMEN1ALDH1A1L3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3966226-B1 MASP INHIBITORY COMPOUNDS AND USES THEREOF BAYER AG (DE) 2025-12-24 EP disclosed
US-12503491-B2 MASP inhibitory compounds and uses thereof BAYER AKTIENGESELLSCHAFT (DE) 2025-12-23 US disclosed
US-20240124522-A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2024-04-18 US disclosed
US-11667675-B2 MASP inhibitory compounds and uses thereof BAYER AKTIENGESELLSCHAFT (DE) 2023-06-06 US disclosed
US-20210246166-A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2021-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12503491-B2 MASP inhibitory compounds and uses thereof MASP2, SERPINB1, SPINT2 KMT2A 4690/4885MEN1 537/4885ALDH1A1 2138/4885
US-11667675-B2 MASP inhibitory compounds and uses thereof MASP2, SERPINB1, SPINT2 KMT2A 4690/4885MEN1 537/4885ALDH1A1 2138/4885
US-20240124522-A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF MASP2, SERPINB1, SPINT2 KMT2A 4690/4885MEN1 537/4885ALDH1A1 2138/4885
US-20210246166-A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF MASP2, SERPINB1, SPINT2 KMT2A 4690/4885MEN1 537/4885ALDH1A1 2138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.